In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)

Hoban, Daryl J.; Bouchillon, S.; Johnson, Brian; Johnson, J.; Dowzicky, M.

doi:10.1016/j.diagmicrobio.2005.06.001

Cited by 146 publications

(71 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, tigecycline exhibited potent in vitro activity by BMD against the indication-relevant pathogens, and the overall pattern of activity by MIC 90 was similar to previously published tigecycline surveillance studies (2,9,10,16,18), with potent activity against resistant gram-positive isolates and activity against Enterobacteriaceae and Acinetobacter spp. Interestingly, the MIC 90 against S. pneumoniae (0.03 g/ml) by BMD was lower than that reported in other U.S.-based surveillances (2, 10), while the MIC 90 against E. faecalis (0.5 g/ml by BMD) was slightly higher (10).…”

Section: Discussionsupporting

confidence: 79%

“…As a new agent designated for use in a nosocomial environment, the constant monitoring of tigecycline activity against pathogens for which it is indicated is of heightened importance. Surveillance of tigecycline against target pathogens has been addressed by multiple ongoing centralized surveillance initiatives (2,10,16,18), where geographically distributed isolates are tested by BMD according to CLSI criteria (4,5).…”

Section: Discussionmentioning

confidence: 99%

“…As a new agent, surveillance of the activity of tigecycline against its target pathogens has been widely reported (2,6,9,10,18) and is critical for both its ongoing clinical development and for the detection of any changes in susceptibility patterns. Surveillance programs can be accomplished in a variety of fashions (distributed, local network reporting, and centralized) and can use a variety of testing methodologies (broth microdilution, Etest, disk diffusion, and automated systems).…”

mentioning

confidence: 99%

See 2 more Smart Citations

In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest

Pillar

Draghi

Dowzicky³

et al. 2008

J Clin Microbiol

Self Cite

View full text Add to dashboard Cite

The current surveillance establishes the activity profile of tigecycline against recent clinical U.S. isolates of target pathogens. Findings from a distributed surveillance that utilized Etest yielded a tigecycline activity profile that varied from that observed in a separate centralized broth microdilution (BMD) surveillance (D. C. Draghi et al., Poster D-0701, 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA). Differences were noted among Acinetobacter spp. and Serratia marcescens and, to a lesser extent, with Streptococcus pyogenes. To address whether these differences were due to discordance in testing methodology or to variations among the analyzed populations, isolates from the current surveillance were concurrently tested by BMD and Etest. In all, 1,800 Staphylococcus aureus, 259 S. pyogenes, 226 Streptococcus pneumoniae, 93 Enterococcus faecalis, 1,356 Enterobacteriaceae, and 227 Acinetobacter baumannii strains were evaluated. Tigecycline had potent activity by BMD, with >99.6% susceptibility (%S) observed for all pathogens with interpretive criteria, excluding Enterobacter cloacae (98.3% S) and E. faecalis (86.0% S), and MIC 90 s ranged from 0.03 g/ml (S. pyogenes/S. pneumoniae) to 1 g/ml (Enterobacteriaceae/A. baumannii). Similar profiles were observed by Etest, with the exception of A. baumannii, although for most evaluated pathogens Etest MICs trended one doubling-dilution higher than BMD MICs. Major or very major errors were infrequent, and a high degree of essential agreement was observed, excluding A. baumannii, S. marcescens, and S. pneumoniae, for which >4-fold differences in MICs were observed for 29, 27.1, and 34% of the isolates, respectively. Further analysis regarding the suitability of the tigecycline Etest for testing S. marcescens, Acinetobacter spp., and S. pneumoniae is warranted.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest

Pillar

Draghi

Dowzicky³

et al. 2008

J Clin Microbiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, in contrast to the classical tetracyclines, tigecycline was not subject to efflux through the tetracycline specific efflux pumps or affected by the ribosomal protection mechanism of tetracycline resistance (11,14,18). In addition, tigecycline showed a good profile against important clinical pathogens: methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate resistant S. aureus (and heterogeneous glycopeptide-intermediate resistant S. aureus), vancomycin-resistant enterococci, penicillin-resistant Streptococcus pneumoniae, and resistant gram-negative aerobic bacilli producing extended-spectrum ␤-lactamases (4,(12)(13)(14)18).…”

mentioning

confidence: 99%

Validation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest

Bolmström¹,

Karlsson²,

Engelhardt³

et al. 2007

J Clin Microbiol

View full text Add to dashboard Cite

A multicenter study was conducted to validate Etest tigecycline compared to the Clinical Laboratory Standards Institute reference broth microdilution and agar dilution methodologies. A large collection of gram-negative (n ‫؍‬ 266) and gram-positive (n ‫؍‬ 162) aerobic bacteria, a collection of anaerobes (n ‫؍‬ 385), and selected collections of nonpneumococcal streptococci (n ‫؍‬ 369), Streptococcus pneumoniae (n ‫؍‬ 372), and Haemophilus influenzae (n ‫؍‬ 372) were tested. Strains with reduced susceptibility to tigecycline were used with all test methods. The Etest showed excellent inter-and intralaboratory reproducibility for all organism groups tested regardless of the test methodology. The essential agreement values with the reference method (؎1 dilution) were >99% for the collection of gram-negative and gram-positive aerobes; >98% for the S. pneumoniae, H. influenzae, and anaerobe collections; and 100% for the group of nonpneumococcal streptococci. These results validate the performance accuracy and utility of Etest tigecycline and verify the reproducibility of this convenient predefined gradient methodology for tigecycline susceptibility determination.

show abstract

“…Se han publicado varios estudios donde se demuestra la actividad tanto in vitro como in vivo de tigeciclina contra Kpn KPC, en los que más de 90% de los aislados son sensibles [5][6]11,12 . Aunque tigeciclina no está aprobada para ser usada en pediatría, existen infecciones por microorganismos multi-resistentes que hacen planteable su utilización 13,14 .…”

Section: Discussionunclassified

Experiencia con el uso compasivo de tigeciclina en pacientes pediátricos infectados por Klebsiella pneumoniae productora de carbapenemasas

Hurtado

Trujillo

Restrepo

et al. 2012

Rev. chil. infectol.

View full text Add to dashboard Cite

Experiencia con el uso compasivo de tigeciclina en pacientes pediátricos infectados por Klebsiella pneumoniae productora de carbapenemasas Isabel C. Hurtado, Mónica Trujillo, Andrea Restrepo, Carlos Garcés, Carolina Tamayo y Juan G. MesaExperience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae Introduction: Infections produced by multidrug-resistant pathogens represent a therapeutic challenge because of the few therapeutic options available. Tigecycline is a relatively new antibiotic, with a wide spectrum of activity including some of these resistant bacteria. In adults is prescribed for the treatment of some infections caused by carbapenem resistant K. pneumoniae, however it has not been approved in children because of potential adverse effects in the dental enamel. Materials and Methods: Case series study. Medical records were reviewed in all children from 0 to 14 years of age that received tigecycline between January of 2008 and March of 2010. Results: 9 patients received Tigecycline mainly for treatment of peritonitis, bacteremia, pneumonia and sepsis caused by carbapenem resistant K. pneumoniae. A dose of 1 mg/kg q 12 hours was administered to all patients. No adverse events were reported and a total of 6 patients had complete resolution of the infection. Conclusions: Tigecycline could be considered a therapeutic option for treating infections produced by multidrug-resistant pathogens in children. The use in children is still compassionate and in this serie of cases Tigecycline was well tolerated and safe.

show abstract

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)

Cited by 146 publications

References 26 publications

In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest

In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest

Validation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest

Experiencia con el uso compasivo de tigeciclina en pacientes pediátricos infectados por Klebsiella pneumoniae productora de carbapenemasas

Contact Info

Product

Resources

About